| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TGFBRAP1 |
| Uniprot No | Q8WUH2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 601-860aa |
| 氨基酸序列 | RGSHHHHHHGMASMTGGQQMGRDLYDDDDKDRWGSKRLQKEEYHTHLAVL YLEEVLLQRASASGKGAEATETQAKLRRLLQKSDLYRVHFLLERLQGAGL PMESAILHGKLGEHEKALHILVHELQDFAAAEDYCLWCSEGRDPPHRQQL FHTLLAIYLHAGPTAHELAVAAVDLLNRHATEFDAAQVLQMLPDTWSVQL LCPFLMGAMRDSIHARRTMQVALGLARSENLIYTYDKMKLKGSSIQLSDK KLCQICQNPFCEPVFVRYPNGGLVHTHCAASRHTNPSSSSPGTRT |
| 预测分子量 | 33 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TGFBRAP1重组蛋白的3篇模拟参考文献示例：
1. **文献名称**：**"Functional characterization of TGFBRAP1 in TGF-β signaling through recombinant protein interaction studies"**
**作者**：Lee et al.
**摘要**：研究通过表达纯化TGFBRAP1重组蛋白，发现其作为TGF-β受体复合物的辅助因子，促进Smad蛋白的磷酸化，并调控下游基因转录。
2. **文献名称**：**"Structural analysis of TGFBRAP1 recombinant protein reveals a critical role in receptor endocytosis"**
**作者**：Zhang et al.
**摘要**：利用X射线晶体学解析TGFBRAP1重组蛋白结构，揭示其通过磷酸化依赖的构象变化参与TGF-β受体内吞过程，影响信号衰减。
3. **文献名称**：**"TGFBRAP1 knockdown and recombinant rescue experiments validate its role in cancer metastasis"**
**作者**：Wang et al.
**摘要**：通过体外重组TGFBRAP1蛋白回补实验，证明其抑制TGF-β诱导的上皮间质转化(EMT)，并降低乳腺癌细胞的侵袭能力。
(注：上述文献为模拟示例，实际研究中需通过PubMed等数据库检索真实文献。)
TGFBRAP1 (Transforming Growth Factor Beta Receptor-Associated Protein 1) is a cytoplasmic protein that plays a regulatory role in the TGF-β signaling pathway, a critical pathway involved in cell proliferation, differentiation, apoptosis, and immune response. It interacts directly with the TGF-β type I receptor (TβRI) and type II receptor (TβRII), stabilizing the receptor complex and modulating downstream signal transduction. Structurally, TGFBRAP1 contains tetratricopeptide repeat (TPR) domains, which mediate protein-protein interactions, and a conserved C-terminal region essential for its function.
Recombinant TGFBRAP1 protein is engineered using expression systems like *E. coli* or mammalian cells to produce purified, biologically active forms for research. This recombinant protein enables studies on TGF-β signaling mechanisms, particularly its role in receptor trafficking, ubiquitination, and degradation. Dysregulation of TGFBRAP1 has been implicated in diseases such as cancer, fibrosis, and cardiovascular disorders, where aberrant TGF-β signaling contributes to pathogenesis. For example, reduced TGFBRAP1 expression may enhance TGF-β signaling, promoting tumor progression or tissue fibrosis.
Researchers utilize recombinant TGFBRAP1 to investigate its interactions with SMAD proteins, co-receptors, or E3 ubiquitin ligases, shedding light on its dual role as a scaffold and regulatory protein. It also serves as a tool for drug discovery, aiming to develop therapies targeting TGF-β pathway components. Quality control of the recombinant protein involves verifying purity (via SDS-PAGE), activity (e.g., binding assays), and structural integrity (mass spectrometry). Challenges include maintaining post-translational modifications in non-mammalian systems, which may require optimized expression platforms. Overall, recombinant TGFBRAP1 is vital for dissecting TGF-β signaling complexity and exploring therapeutic interventions.
×
